TPST
ANALYST COVERAGE4 analysts
BUY
Buy
4100%
4 Buy (100%)0 Hold (0%)0 Sell (0%)
Full report →
Key MetricsTTM
Market Cap$8.26M
Revenue TTM$0.00
Net Income TTM-$43.10M
Free Cash Flow-$26.38M
Gross Margin
Operating Margin
Net Margin
Return on Equity-729.9%
Return on Assets
Debt / Equity9.55
Current Ratio0.74
EPS TTM$-3.94
PRICE
Prev Close
1.81
Open
1.86
Day Range1.84 – 1.95
1.84
1.95
52W Range1.50 – 12.23
1.50
12.23
3% of range
VOLUME & SIZE
Avg Volume
205.7K
FUNDAMENTALS
P/E Ratio
-0.3x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
1.36
Market-like
TECHNICAL
RSI (14)
47
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 24
DEx-Dividend
In 90 days
Aug 21
PDividend Pay
In 128 days
Sep 28

TPST News

About

tempest therapeutics is a development-stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor immunity pathways. tempest has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct immune response pathways relevant to mounting an effective anti-tumor response. the molecules were developed by inception sciences, a versant ventures affiliated drug discovery engine. tempest has assembled a highly experienced team of small molecule and immuno-oncology drug developers to advance these programs to the clinic across diverse cancers representing significant unmet medical need. tempest is backed by a syndicate of leading us and china based venture capital firms.

Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Julia Owens
Country
United States
Matthew AngelChief Executive Officer, President & Director
Andrew FangHead of Business Development
Justin TrojanowskiCorporate Controller, Treasurer & Principal Accounting Officer
Nicholas MaestasChief Financial Officer, Head of Corporate Strategy & Secretary